Kura Oncology KURA Business Segments
| FY'25 | FY'24 | FY'23 | ||
|---|---|---|---|---|
| Revenue Not From Contract With Customer by Product | ||||
| Development Services For Monotherapy | $28M+5,500% | $500K— | —— | |
| Development Services In Combination With Other Therapies | $19.3M+2,313% | $800K— | —— | |
| Research And Development Expense by Product | ||||
| Darlifarnib | $26.71M— | —— | $10.63M— | |
| Discovery Stage Program | $7.23M+9.2% | $6.62M+22.6% | $5.4M+112% | |
| Ziftomenib | $142.58M+79.7% | $79.34M+121% | $35.93M+70.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Kura Oncology break its business down?
- Kura Oncology (KURA) reports revenue by product across 3 parts — Development Services For Monotherapy, Development Services In Combination With Other Therapies and License And Collaboration Revenue. Each is extracted from the segment footnotes and tracked over time.
- Where does Kura Oncology's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Kura Oncology's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
